{
    "id": 30672,
    "fullName": "SLFN11 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SLFN11 positive indicates the presence of the SLFN11 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 91607,
        "geneSymbol": "SLFN11",
        "terms": [
            "SLFN11",
            "SLFN8/9"
        ]
    },
    "variant": "positive",
    "createDate": "08/05/2019",
    "updateDate": "08/05/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17941,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Temodar (temozolomide) and Veliparib (ABT-888) combination treatment resulted in improved progression-free survival (5.7 vs 3.6 months, p=0.009) and overall survival (12.2 vs 7.5 months, p=0.014) in patients with SLFN11-positive (n=12) small cell lung cancer compared to patients with SLFN11-negative (n=14) tumors (PMID: 29906251; NCT01638546).",
            "molecularProfile": {
                "id": 32904,
                "profileName": "SLFN11 positive"
            },
            "therapy": {
                "id": 1193,
                "therapyName": "Temozolomide + Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 5409,
                "name": "lung small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15905,
                    "pubMedId": 29906251,
                    "title": "Randomized, Double-Blind, Phase II Study of Temozolomide in Combination With Either Veliparib or Placebo in Patients With Relapsed-Sensitive or Refractory Small-Cell Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29906251"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        }
    ],
    "molecularProfiles": [
        {
            "id": 32904,
            "profileName": "SLFN11 positive",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}